SCHEMBL23952192

SCHEMBL23952192

CCCc1cc2c(=O)n(CC(=O)OCC)nc(C(C)C)n2c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.43
POLB P06746 2/20 0.41
NLRP3 Q96P20 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM4E B2RXH2 4/20 0.40
GAA P10253 1/20 0.40
ALDH1A1 P00352 3/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.38
MAPK8 P45983 1/20 0.37
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HSD17B10 Q99714 1/20 0.37
BRD4 O60885 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23952562 0.91 GAA (0.44) CYP2C19POLBNLRP3CYP2C9CYP1A2
SCHEMBL25815549 0.87 NLRP3 (0.44) POLBNLRP3MEN1KMT2A
SCHEMBL23952011 0.86 CYP2C19 (0.46) CYP2C19POLBNLRP3CYP2C9CYP1A2
SCHEMBL23952567 0.85 NLRP3 (0.50) CYP2C19POLBNLRP3CYP2C9CYP1A2
SCHEMBL23925366 0.84 NLRP3 (0.57) CYP2C19POLBNLRP3CYP2C9CYP1A2
SCHEMBL23952008 0.84 MAPK8 (0.44) CYP2C19POLBNLRP3CYP2C9CYP1A2
SCHEMBL23952007 0.84 POLB (0.48) CYP2C19POLBNLRP3CYP2C9CYP1A2
SCHEMBL23925404 0.84 NLRP3 (0.42) CYP2C19POLBNLRP3CYP2C9CYP1A2
SCHEMBL23925349 0.83 NLRP3 (0.42) CYP2C19POLBNLRP3CYP2C9CYP1A2
SCHEMBL23925373 0.83 NLRP3 (0.44) CYP2C19POLBNLRP3CYP2C9CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230183248-A1 PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY JANSSEN PHARMACEUTICA NV (BE) 2023-06-15 US disclosed
US-20230183248-A1 PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY JANSSEN PHARMACEUTICA NV (BE) 2023-06-15 US disclosed
WO-2021209539-A1 PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY JANSSEN PHARMACEUTICA NV (BE) 2021-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230183248-A1 PYRROLO[1,2-D][1,2,4]TRIAZINE-2-YL-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY NLRP3, NLRP1, IL1B CYP2C19 2017/4885POLB 3251/4885NLRP3 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.